Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review
The Programmed death-1 (PD-1) and its programmed death-ligand 1 (PD-L1) comprise the PD-1/PD-L1 axis and maintain tumor immune evasion. Cancer immunotherapy based on anti-PD-1/PD-L1 antibodies is the most promising anti-tumor treatment available but is currently facing the thorny problem of unsatisf...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1168226/full |
| _version_ | 1797802679872782336 |
|---|---|
| author | Huilan Zheng Gang Wang Ming Liu Hongbin Cheng |
| author_facet | Huilan Zheng Gang Wang Ming Liu Hongbin Cheng |
| author_sort | Huilan Zheng |
| collection | DOAJ |
| description | The Programmed death-1 (PD-1) and its programmed death-ligand 1 (PD-L1) comprise the PD-1/PD-L1 axis and maintain tumor immune evasion. Cancer immunotherapy based on anti-PD-1/PD-L1 antibodies is the most promising anti-tumor treatment available but is currently facing the thorny problem of unsatisfactory outcomes. Traditional Chinese Medicine (TCM), with its rich heritage of Chinese medicine monomers, herbal formulas, and physical therapies like acupuncture, moxibustion, and catgut implantation, is a multi-component and multi-target system of medicine known for enhancing immunity and preventing the spread of disease. TCM is often used as an adjuvant therapy for cancer in clinical practices, and recent studies have demonstrated the synergistic effects of combining TCM with cancer immunotherapy. In this review, we examined the PD-1/PD-L1 axis and its role in tumor immune escape while exploring how TCM therapies can modulate the PD-1/PD-L1 axis to improve the efficacy of cancer immunotherapy. Our findings suggest that TCM therapy can enhance cancer immunotherapy by reducing the expression of PD-1 and PD-L1, regulating T-cell function, improving the tumor immune microenvironment, and regulating intestinal flora. We hope this review may serve as a valuable resource for future studies on the sensitization of immune checkpoint inhibitors (ICIs) therapy. |
| first_indexed | 2024-03-13T05:09:21Z |
| format | Article |
| id | doaj.art-dc1f3322d1884271965704aa3cccdac0 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-13T05:09:21Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dc1f3322d1884271965704aa3cccdac02023-06-16T05:35:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-06-011310.3389/fonc.2023.11682261168226Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature reviewHuilan Zheng0Gang Wang1Ming Liu2Hongbin Cheng3Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Medical Oncology/Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaThe Programmed death-1 (PD-1) and its programmed death-ligand 1 (PD-L1) comprise the PD-1/PD-L1 axis and maintain tumor immune evasion. Cancer immunotherapy based on anti-PD-1/PD-L1 antibodies is the most promising anti-tumor treatment available but is currently facing the thorny problem of unsatisfactory outcomes. Traditional Chinese Medicine (TCM), with its rich heritage of Chinese medicine monomers, herbal formulas, and physical therapies like acupuncture, moxibustion, and catgut implantation, is a multi-component and multi-target system of medicine known for enhancing immunity and preventing the spread of disease. TCM is often used as an adjuvant therapy for cancer in clinical practices, and recent studies have demonstrated the synergistic effects of combining TCM with cancer immunotherapy. In this review, we examined the PD-1/PD-L1 axis and its role in tumor immune escape while exploring how TCM therapies can modulate the PD-1/PD-L1 axis to improve the efficacy of cancer immunotherapy. Our findings suggest that TCM therapy can enhance cancer immunotherapy by reducing the expression of PD-1 and PD-L1, regulating T-cell function, improving the tumor immune microenvironment, and regulating intestinal flora. We hope this review may serve as a valuable resource for future studies on the sensitization of immune checkpoint inhibitors (ICIs) therapy.https://www.frontiersin.org/articles/10.3389/fonc.2023.1168226/fulltraditional Chinese medicinecancer immunotherapysensitizationimmune checkpoint inhibitorPD-1/PD-L1 axis |
| spellingShingle | Huilan Zheng Gang Wang Ming Liu Hongbin Cheng Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review Frontiers in Oncology traditional Chinese medicine cancer immunotherapy sensitization immune checkpoint inhibitor PD-1/PD-L1 axis |
| title | Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review |
| title_full | Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review |
| title_fullStr | Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review |
| title_full_unstemmed | Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review |
| title_short | Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review |
| title_sort | traditional chinese medicine inhibits pd 1 pd l1 axis to sensitize cancer immunotherapy a literature review |
| topic | traditional Chinese medicine cancer immunotherapy sensitization immune checkpoint inhibitor PD-1/PD-L1 axis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1168226/full |
| work_keys_str_mv | AT huilanzheng traditionalchinesemedicineinhibitspd1pdl1axistosensitizecancerimmunotherapyaliteraturereview AT gangwang traditionalchinesemedicineinhibitspd1pdl1axistosensitizecancerimmunotherapyaliteraturereview AT mingliu traditionalchinesemedicineinhibitspd1pdl1axistosensitizecancerimmunotherapyaliteraturereview AT hongbincheng traditionalchinesemedicineinhibitspd1pdl1axistosensitizecancerimmunotherapyaliteraturereview |